Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 18/20 | 0.50 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.48 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16694505 | 0.80 | HIF1A (0.55) | HIF1AEPAS1EP300HSP90AA1 | |
| SCHEMBL22420323 | 0.74 | HSP90AA1 (0.41) | HIF1AEPAS1HSP90AA1ACHE | |
| SCHEMBL22420354 | 0.73 | HIF1A (0.48) | HIF1AEPAS1EP300HSP90AA1 | |
| SCHEMBL22420294 | 0.71 | HIF1A (0.46) | HIF1AEPAS1EP300HSP90AA1ACHE | |
| SCHEMBL18244769 | 0.69 | HIF1A (0.80) | HIF1AHSP90AA1 | |
| SCHEMBL6656697 | 0.68 | PPARG (0.61) | ACHE | |
| SCHEMBL11820012 | 0.67 | SMN1; SMN2 (0.52) | HIF1AEPAS1ACHE | |
| SCHEMBL16694230 | 0.67 | HIF1A (0.67) | HIF1AEPAS1HSP90AA1 | |
| SCHEMBL16694335 | 0.67 | HIF1A (1.00) | HIF1AHSP90AA1 | |
| SCHEMBL16694313 | 0.67 | HIF1A (0.67) | HIF1AEPAS1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772858-B2 | Benzhydrol derivatives for the management of conditions related to hypoxia inducible factors | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772858-B2 | Benzhydrol derivatives for the management of conditions related to hypoxia inducible factors | HIF1A, HIF1AN, EGLN2 | HIF1A 1/4885EPAS1 26/4885EP300 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.